p. 951−957
2090-7125
Vol.80/No.3
p. 958−963
2090-7125
Vol.80/No.3
p. 964−970
2090-7125
Vol.80/No.3
p. 971−976
2090-7125
Vol.80/No.3
p. 977−985
2090-7125
Vol.80/No.3
p. 986−989
2090-7125
Vol.80/No.3
p. 990−996
2090-7125
Vol.80/No.3
p. 997−1002
2090-7125
Vol.80/No.3
p. 1003−1007
2090-7125
Vol.80/No.3
p. 1008−1013
2090-7125
Vol.80/No.3
0.05). None of the studied VEGF genotypes had shown significant difference in distribution related to clinico-pathological parameters as tumor size, histological grade, hormone receptors, HER2/new status, regional lymph node and distant metastasis (p>0.05). Conclusion: This study revealed that there was no significant association of the (C/C, T/C and T/T) genotypes of VEGF 460T/C (rs833061) and breast cancer risk. Moreover, VEGF polymorphism 460T/C (rs833061) was not associated with breast cancer patients’ clinico-pathological characteristics and tumor markers levels. ]]>
p. 1014−1018
2090-7125
Vol.80/No.3
p. 1019−1026
2090-7125
Vol.80/No.3
0.05 for each), there were no statistically significant correlations between the GUESS scores and any of the clinical characteristics of FM patients. Although non-significant, these correlations were negative between the GUESS score and the tender point number, the Widespread Pain Index as well as the Fibromyalgia Impact Questionnaire. The total GUESS score of the FM group ranged between 0-12 with a mean ±SD of 5.3 ± 2.8. The total GUESS score of control group ranged between 0-6 with a mean ±SD of 0.97± 1.58, with a significant difference between the two groups (P<0.05) Conclusion: There were significant enthesopathic changes detected among FM patients especially affecting the Achilles, quadriceps, and proximal patellar tendons.]]>
p. 1027−1034
2090-7125
Vol.80/No.3
p. 1035−1043
2090-7125
Vol.80/No.3
p. 1044−1045
2090-7125
Vol.80/No.3
p. 1046−1053
2090-7125
Vol.80/No.3
p. 1054−1059
2090-7125
Vol.80/No.3
p. 1060−1066
2090-7125
Vol.80/No.3
p. 1067−1073
2090-7125
Vol.80/No.3
p. 1074−1078
2090-7125
Vol.80/No.3
p. 1079−1085
2090-7125
Vol.80/No.3
0.05) between studied groups as regards metabolic syndrome prevalence. There was high statistical significant difference (p-value < 0.001) between patients with MS and patients without MS in RA group regarding age, duration, BMI, FBS, ESR, CRP and DAS28. High statistical significant difference (p-value < 0.001) was detected between patients with MS and patients without MS in SPA group as regards duration, BMI, FBS and BASDI. There was increase in cIMT in RA (0.8 ± 0.2) and SPA groups (0.7 ± 0.1) with high statistical significant difference (p-value < 0.001). Conclusion: MS prevalence increased in patients with RA and SPA, whereas the cardiovascular risks increased in RA patients. The disease activity of both were associated with metabolic syndrome, implicating the role of chronic inflammation in metabolic syndrome development. ]]>
p. 1086−1091
2090-7125
Vol.80/No.3
p. 1092−1096
2090-7125
Vol.80/No.3
p. 1097−1102
2090-7125
Vol.80/No.3
0.05). There was no association between the post-debulking CCCs and the 3-year progression-free survival (PFS) (P>0.05) or the overall survival (OS) (P>0.05). There was an association between frequent presence of lymph node involvement and the presence of post-debulking CCCs (P<0.01). However not significant, there was an association between the post-debulking CCCs and the PFS in women with very advanced cancers (P>0.05). Conclusion: The presence of post-debulking CCCs was proven to be associated with bad prognosis as it showed to be associated with poor PFS. Further studies are required to enforce these findings. ]]>
p. 1103−1109
2090-7125
Vol.80/No.3
p. 1110−1115
2090-7125
Vol.80/No.3
p. 1116−1125
2090-7125
Vol.80/No.3
p. 1126−1137
2090-7125
Vol.80/No.3
p. 1138−1143
2090-7125
Vol.80/No.3
p. 1144−1150
2090-7125
Vol.80/No.3